![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Chronic inflammatory demyelinating polyradiculopathy is an immune-mediated neuropathy that was first described approximately 30 years ago. Since that time an increasingly wide spectrum of chronic acquired demyelinating polyneuropathies exhibiting different phenotypes, clinical course and treatment responses to immunomodulatory treatment have been described. Several new therapeutic agents have been prescribed for such conditions, some with promising results. This review summarizes what is presently known about the clinical courses, treatment responses and predictors of response of the chronic inflammatory demyelinating polyradiculopathy subgroups.
Keywords::
- azathioprine
- ciclosporin
- chronic inflammatory demyelinating polyradiculoneuropathy
- CIDP
- cyclophosphamide
- etanercept
- IgM paraproteinemic demyelinating neuropathy
- interferon
- IVIg
- MADSAM
- methotrexate
- MMN
- multifocal acquired demyelinating sensory and motor neuropathy
- multifocal motor neuropathy
- mycophenolate
- plasma exchange
- rituximab
- steriods